FrancisPaulWordenMD

Oncology • Ann Arbor, MI

Endocrine Cancer, Head & Neck Cancer, Hematologic Oncology

Assistant Clinical Professor of Medicine, University Mich Medical School

Join to view full profile

Dr. Worden is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Worden's full profile

Already have an account?

Office
1500 East Medical Center Dr
B1 Floor Cancer Ctr Recp C
Ann Arbor, MI 48109
Phone+1 734-647-8902
Is this information wrong?

Summary

I am a medical oncologist at the University of Michigan. I specialize in the treatment of head and neck cancers and endocrine malignancies and conduct clinical trials related to these disease entities.

Education & Training

University of Michigan Health SystemFellowship, Hematology and Medical Oncology, 1997 - 2000
Detroit Medical Center/Wayne State UniversityResidency, Internal Medicine/Pediatrics, 1993 - 1997
Indiana University School of MedicineClass of 1993

Certifications & Licensure

MI State Medical License 1997 - 2025
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

America's Top Doctors for Cancer Castle Connolly, 2005-2014
America's Top Doctors Castle Connolly, 2009-2014
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Trial Evaluating Gleevec in Patients With Anaplastic Thyroid Carcinoma Start of enrollment: 2004 Feb 01
Terminated
Phase 2
A Study of a New Combination and Schedule of Chemotherapy Drugs for the Treatment of Head and Neck Cancer Start of enrollment: 2002 Nov 01
Completed
Phase 2
Treatment for Patients With Metastatic Thyroid Cancer Start of enrollment: 2005 Jul 01
Completed
Phase 2
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Everolimus Versus Placebo in Head and Neck Cancer Start of enrollment: 2010 Apr 01
Terminated
Phase 2
Cediranib Maleate With or Without Lenalidomide for the Treatment of Thyroid Cancer Start of enrollment: 2010 Sep 09
Completed
Phase 1, Phase 2
A Study of AT-101 in Combination With Docetaxel in Squamous Cell Carcinoma Of The Head and Neck Start of enrollment: 2010 Jun 01
Terminated
Phase 2
Phase II Trial Evaluating Axitinib In Patients With Unresectable, Recurrent Or Metastatic Head And Neck Cancer Start of enrollment: 2012 Jan 01
Completed
Phase 2
Cetuximab With or Without Tivantinib in Treating Patients With Head and Neck Cancer That Is Recurrent, Metastatic, or Cannot Be Removed by Surgery Start of enrollment: 2012 Aug 20
Completed
Phase 2
A Phase II Trial of Proton Pump Inhibitors With Chemotherapy in Patients With Metastatic Head and Neck Cancer Start of enrollment: 2013 Dec 01
Withdrawn
Phase 2
A Randomized Comparative Study of a Weekly Versus Every Other Week Nurse Practitioner-led Symptom Management Clinic for Head and Neck Cancer Patients Undergoing Concurrent Chemotherapy and Radiation Start of enrollment: 2014 Mar 01
Withdrawn
Not Applicable
Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Head and Neck Carcinoma (CheckMate 141) Start of enrollment: 2014 May 29
Completed
Phase 3
A Phase II Trial Evaluating WNT974 in Patients With Metastatic Head and Neck Squamous Cell Carcinoma
Withdrawn
Phase 2
Expansion Trial for Axitinib In Head And Neck Cancer Start of enrollment: 2016 Aug 30
Completed
Phase 2
Phase II Treatment Stratification Trial Using Neck Dissection-Driven Selection to Improve Quality of Life for Low Risk Patients With HPV+ Oropharyngeal Squamous Cell Cancer Start of enrollment: 2016 Oct 31
Completed
Phase 2
Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) Start of enrollment: 2018 Feb 07
Completed
Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer Start of enrollment: 2017 Apr 27
Recruiting
Phase 2
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence Start of enrollment: 2018 Aug 20
Recruiting
Phase 3
Roles: Principal Investigator, Contact
Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Start of enrollment: 2021 Feb 26
Recruiting
Phase 2
Roles: Principal Investigator, Contact
Join now to see all

Publications & Presentations

PubMed

Targeted Therapy and Immunotherapy for Advanced Malignant Conjunctival Tumors: Systematic Review.
Serbest Ceylanoglu, K., Guneri Beser, B., Singalavanija, T., Juntipwong, S., Worden, F., Demirci, H.> ;Ophthalmic Plastic and Reconstructive Surgery. 2024 Jan 18
Use of Cemiplimab, an Immune Checkpoint Inhibitor for Conjunctival Intraepithelial Neoplasia.
Ceylanoglu, K., Eisenberg, A., Elner, V., Worden, F., Demirci, H.> ;Cornea. 2024 Apr 1
Real-world practice patterns and outcomes for RAI-refractory differentiated thyroid cancer.
Choe, J., Babajanyan, S., Gianoukakis, A., Bowles, D., Owonikoko, T., Worden, F., Wirth, L., Brose, M.> ;European Thyroid Journal. 2024 Feb 1
A Phase II Trial of Rivoceranib, an Oral Vascular Endothelial Growth Factor Receptor 2 Inhibitor, for Recurrent or Metastatic Adenoid Cystic Carcinoma.
Glenn J Hanna, Myung-Ju Ahn, Jameel Muzaffar, Bhumsuk Keam, Daniel W Bowles, Deborah J Wong, Alan L Ho, Sung-Bae Kim, Francis Worden, Tak Yun, Xianzhang Meng, Jan M Va...> ;Clinical Cancer Research. 2023 Nov 14
Real-World Use of Systemic Therapies for the Treatment of Advanced Thyroid Cancers.
Debbie W Chen, Mousumi Banerjee, Tianyi Xu, Francis P Worden, Megan R Haymart> ;Endocrine Practice. 2023 Nov 1
1 citations
Review of Targeted Therapy, Vismodegib, for the Treatment of Periocular Basal Cell Carcinoma.
Tassapol Singalavanija, Kubra Serbest Ceylanoglu, Sarinee Juntipwong, Buse Guneri Beser, Victor Maurice Elner, Francis Paul Worden, Hakan Demirci> ;Ophthalmic Plastic and Reconstructive Surgery. 2023 Aug 8
1 citations
A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.
A J Rosenberg, C-Y Liao, T Karrison, J A de Souza, F P Worden, B Libao, M K Krzyzanowska, D N Hayes, E Winquist, V Saloura, K Prescott, V M Villaflor, T Y Seiwert, R B...> ;Annals of Oncology. 2023 Aug 1
2 citations
Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols.
Catherine T Haring, Lulia A Kana, Sarah M Dermody, Collin Brummel, Jonathan B McHugh, Keith A Casper, Steven B Chinn, Kelly M Malloy, Michelle Mierzwa, Mark E P Prince...> ;Cancer. 2023 Sep 15
1 citations
Access Denied: Disparities in Thyroid Cancer Clinical Trials.
Debbie W Chen, Francis P Worden, Megan R Haymart> ;Journal of the Endocrine Society. 2023 May 5
Impact of monoclonal antibody therapy for head and neck cancer on end-of-life care utilization and costs.
William J Benjamin, Pratyusha Yalamanchi, Jeremy M G Taylor, Nicholas Lenze, Francis P Worden, Steven B Chinn, Michelle M Chen> ;Head & Neck. 2023 Jun 1
3 citations
Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer.
Joshua D Smith, Megan L Ludwig, Apurva D Bhangale, Collin Brummel, Paul L Swiecicki, Francis P Worden, Steven B Chinn, Chaz L Stucken, Andrew J Rosko, Mark E P Prince,...> ;Head & Neck. 2023 May 1
2 citations
Initial Feasibility and Acute Toxicity Outcomes From a Phase 2 Trial ofF-Fluorodeoxyglucose Positron Emission Tomography Response-Based De-escalated Definitive Chemora...
Steven G Allen, Benjamin S Rosen, Madhava Aryal, Yue Cao, Matthew J Schipper, Ka Kit Wong, Keith A Casper, Steven B Chinn, Kelly M Malloy, Mark E Prince, Andrew J Rosk...> ;International Journal of Radiation Oncology, Biology, Physics. 2023 Sep 1
2 citations
Machine Learning Model of Emergency Department Use for Patients Undergoing Treatment for Head and Neck Cancer Using Comprehensive Multifactor Electronic Health Records.
Charles S Mayo, Michelle Mierzwa, Pratyusha Yalamanchi, Joseph Evans, Francis Worden, Richard Medlin, Matthew Schipper, Caitlin Schonewolf, Jennifer Shah, Matthew Spec...> ;JCO Clinical Cancer Informatics. 2023 Jan 1
8 citations
Biomarkers predictive of response to pembrolizumab in head and neck cancer.
David G Pfister, Robert I Haddad, Francis P Worden, Jared Weiss, Ranee Mehra, Laura Q M Chow, Stephen V Liu, Hyunseok Kang, Nabil F Saba, Lori J Wirth, Ammar Sukari, E...> ;Cancer Medicine. 2023 Mar 1
3 citations
Prognostic value of CD103tumor-infiltrating lymphocytes and programmed death ligand-1 (PD-L1) combined positive score in recurrent laryngeal squamous cell carcinoma.
Joshua D Smith, Emily L Bellile, Susan E Ellsperman, Molly E Heft-Neal, Jacqueline E Mann, Andrew C Birkeland, Rebecca C Hoesli, Paul L Swiecicki, Francis P Worden, Ca...> ;Oral Oncology. 2022 Dec 1
4 citations
A Randomized Multi-institutional Phase II Trial of Everolimus as Adjuvant Therapy in Patients with Locally Advanced Squamous Cell Cancer of the Head and Neck.
Cherie-Ann O Nathan, D Neil Hayes, Theodore Karrison, Olivier Harismendy, José M Flores, Tara Moore-Medlin, Everett E Vokes, J Silvio Gutkind, Prakash Neupane, Glenn M...> ;Clinical Cancer Research. 2022 Dec 1
3 citations
Randomized Phase II Study of Physiologic MRI-Directed Adaptive Radiation Boost in Poor Prognosis Head and Neck Cancer.
Michelle L Mierzwa, Madhava Aryal, Choonik Lee, Matthew Schipper, Monica VanTil, Krystal Morales, Paul L Swiecicki, Keith A Casper, Kelly M Malloy, Matthew E Spector, ...> ;Clinical Cancer Research. 2022 Dec 1
5 citations
Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI).
Marcia S Brose, Johannes W A Smit, Chia-Chi Lin, Masayuki Tori, Daniel W Bowles, Francis Worden, Daniel Hueng-Yuan Shen, Shih-Ming Huang, Hui-Jen Tsai, Maria Alevizaki...> ;Thyroid. 2022 Sep 1
13 citations
Phase II Study of Enzalutamide for Patients With Androgen Receptor-Positive Salivary Gland Cancers (Alliance A091404).
Alan L Ho, Nathan R Foster, Alex J Zoroufy, Jordan D Campbell, Francis Worden, Katharine Price, Douglas Adkins, Daniel W Bowles, Hyunseok Kang, Barbara Burtness, Eric ...> ;Journal of Clinical Oncology. 2022 Dec 20
1 citations
Randomized trial of laryngeal organ preservation evaluating two cycles of induction chemotherapy with platinum, docetaxel, and a novel Bcl-xL inhibitor.
Paul L Swiecicki, Emily Bellile, Keith Casper, Steven Bennett Chinn, Aleksandar F Dragovic, Shruti Jolly, Robbi Kupfer, Kelly M Malloy, Michelle Lynn Mierzwa, Andrew G...> ;Head & Neck. 2022 Jul 1
4 citations
Differences in tumor-to-normal organ SUV ratios measured with 68 Ga-DOTATATE PET compared with 177 Lu-DOTATATE SPECT in patients with neuroendocrine tumors.
Ka Kit Wong, Kirk A Frey, Jeremy Niedbala, Ravi K Kaza, Francis P Worden, Kellen J Fitzpatrick, Yuni K Dewaraja> ;Nuclear Medicine Communications. 2022 Aug 1
1 citations
Novel Therapeutics for Advanced Differentiated Thyroid Cancer.
Leedor Lieberman, Francis Worden> ;Endocrinology and Metabolism Clinics of North America. 2022 Jun 1
31 citations
Phase II Clinical Trial of Neoadjuvant and Adjuvant Pembrolizumab in Resectable Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma.
Trisha M Wise-Draper, Shuchi Gulati, Sarah Palackdharry, Benjamin H Hinrichs, Francis P Worden, Matthew O Old, Neal E Dunlap, John M Kaczmar, Yash Patil, Muhammed Kash...> ;Clinical Cancer Research. 2022 Apr 1
3 citations
Infrequent liver injury from cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
Linnea Swanson, Ihab Kassab, Irene Tsung, Francis P Worden, Robert J Fontana> ;Immunotherapy. 2022 Apr 1
17 citations
Long-term Outcomes with Nivolumab as First-line Treatment in Recurrent or Metastatic Head and Neck Cancer: Subgroup Analysis of CheckMate 141.
Maura L Gillison, George Blumenschein, Jerome Fayette, Joel Guigay, A Dimitrios Colevas, Lisa Licitra, Kevin J Harrington, Stefan Kasper, Everett E Vokes, Caroline Eve...> ;The Oncologist. 2022 Mar 4
Join now to see all

Journal Articles

Assessment of Clinical Benefit of Integrative Genomic Profiling in Advanced Solid Tumors
Erin F Cobain, Francis Worden, Scott M Schuetze, Mark M Zalupski, Vaibhav Sahai, Ajjai Alva, Anne F Schott, Moshe Talpaz, JAMA Oncology
Efficacy of Selpercatinib in RET-Altered Thyroid Cancers
Lori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine

Lectures

Head and Neck Cancer
ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019
Updates on Current Programs and Resources
2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Other

Postoperative radiation therapy in the management of head and neck cancer
Worden FP, Eisbruch A, Jolly S
http://www.uptodate.com/contents/postoperative-radiation-therapy-in-the-management-of-head-and-neck-
UpToDate, Wolters Kluwer Health - 2012-02-27
Treatment of early (stage I and II) head and neck cancer: The oropharynx
Worden FP, Eisbruch A, Bradford CR
http://www.uptodate.com/contents/treatment-of-early-stage-i-and-ii-head-and-neck-cancer-the-orophary
UpToDate, Wolters Kluwer Health - 2012-10-31
Treatment of locoregionally advanced (stage III and IV) head and neck cancer: The oropharynx
Worden FP, Eisbruch A, Bradford CR
http://www.uptodate.com/contents/treatment-of-locoregionally-advanced-stage-iii-and-iv-head-and-neck
UpToDate, Wolters Kluwer Health - 2012-06-05

Authored Content

Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020
Efficacy of Selpercatinib in RET-Altered Thyroid CancersAugust 2020

Press Mentions

Axitinib Improves Survival for Patients with Incurable Head and Neck CancerOctober 20th, 2020
Racial, Socioeconomic Disparities Found Among Patients with HPV-Positive Oropharyngeal CancerFebruary 6th, 2020
$New Treatments, New Outcomes for Refractory Thyroid Cancer$
New Treatments, New Outcomes for Refractory Thyroid CancerJuly 10th, 2019
Join now to see all